FDA warns Akrimax Pharmaceuticals for improper Facebook marketing

FDA issued a warning to Akrimax Pharmaceuticals for improper advertising of its drug Tirosint. Every company in the world does Facebook marketing these days, but advertising rules for medicines are still applied. The Facebook webpage of the company was false or misleading because it makes representations about the efficacy of Tirosint, but fails to communicate any risk information associated with its use and it omits material facts.

Tirosint is used to treat hypothyroidism and has some warnings related to it like any other medication. Tirosint is associated with number of risks. So, it has to be communicated to people looking at the Facebook page of the drug.

The warning was in the form of an Untitled Letter, a kind of warning letter without any legal threat attached. The letters points out the problem and tells the company to rectify them. The letter mentioned that the Package Insert (PI) for Tirosint includes a Boxed Warning indicating that Tirosint should not be used for the treatment of obesity or for weight loss.